| http://www.w3.org/ns/prov#value | - Although open-label studies have suggested that the clinical efficacy of several SSRIs is enhanced by T3,26- 28 the only randomized, double-blind, placebo-controlled trial besides the present one did not show a clinical advantage for T3 augmentation of the SSRI paroxetine.30 Further controlled studies are needed to address the question of generalizability to SSRIs other than sertraline.
|
